dc.contributor.author
Reimann, Carolin
dc.contributor.author
Brangsch, Julia
dc.contributor.author
Kaufmann, Jan Ole
dc.contributor.author
Adams, Lisa C.
dc.contributor.author
Onthank, David C.
dc.contributor.author
Robinson, Simon P.
dc.contributor.author
Botnar, Rene M.
dc.contributor.author
Collettini, Federico
dc.contributor.author
Makowski, Marcus R.
dc.date.accessioned
2019-04-23T09:30:38Z
dc.date.available
2019-04-23T09:30:38Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/24470
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-2241
dc.description.abstract
Objectives. The aim of this study was to test the potential of a new elastin-specific molecular agent for the performance of contrast-enhanced first-pass and 3D magnetic resonance angiography (MRA), compared to a clinically used extravascular contrast agent (gadobutrol) and based on clinical MR sequences. Materials and Methods. Eight C57BL/6J mice (BL6, male, aged 10 weeks) underwent a contrast-enhanced first-pass and 3D MR angiography (MRA) of the aorta and its main branches. All examinations were on a clinical 3 Tesla MR system (Siemens Healthcare, Erlangen, Germany). The clinical dose of 0.1 mmol/kg was administered in both probes. First, a time-resolved MRA (TWIST) was acquired during the first-pass to assess the arrival and washout of the contrast agent bolus. Subsequently, a high-resolution 3D MRA sequence (3D T1 FLASH) was acquired. Signal-to-noise ratios (SNRs) and contrast-to-noise ratios (CNRs) were calculated for all sequences. Results. The elastin-specific MR probe and the extravascular imaging agent (gadobutrol) enable high-quality MR angiograms in all animals. During the first-pass, the probes demonstrated a comparable peak enhancement (300.6 +/- 32.9 vs. 288.5 +/- 33.1, p > 0.05). Following the bolus phase, both agents showed a comparable intravascular enhancement (SNR: 106.7 +/- 11 vs. 102.3 +/- 5.3; CNR 64.5 +/- 7.4 vs. 61.1 +/- 7.2, p > 0.05). Both agents resulted in a high image quality with no statistical difference (p > 0.05). Conclusion. The novel elastin-specific molecular probe enables the performance of first-pass and late 3D MR angiography with an intravascular contrast enhancement and image quality comparable to a clinically used extravascular contrast agent.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
3D magnetic resonance angiography
en
dc.subject
elastin-specific molecular agent
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Contrast-Enhanced Magnetic Resonance Angiography Using a Novel Elastin-Specific Molecular Probe in an Experimental Animal Model
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
9217456
dcterms.bibliographicCitation.doi
10.1155/2018/9217456
dcterms.bibliographicCitation.journaltitle
Contrast Media & Molecular Imaging
dcterms.bibliographicCitation.originalpublishername
Hindawi Limited
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
30425609
dcterms.isPartOf.issn
1555-4309
dcterms.isPartOf.issn
1555-4317